# A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

> **NCT05335499** · PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 126 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** TAS5315 Dose 1
- **DRUG:** TAS5315 Dose 2
- **DRUG:** TAS5315 Dose 3
- **DRUG:** TAS5315 Dose 4
- **DRUG:** TAS5315 Dose 5
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05335499
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2023-12-22
- **Final completion:** 2023-12-22
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335499, "A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05335499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*